
浏览全部资源
扫码关注微信
无锡市第二人民医院肿瘤内科,江苏 无锡 214002
承婷,E-mail:chengting_ct@yeah.net
收稿:2025-06-24,
纸质出版:2026-03-25
移动端阅览
吴锦伟,承婷.METTL3、IREB2在非小细胞肺癌组织中的表达及意义[J].局解手术学杂志,2026,35(03):240-244.
WU Jin-wei,CHENG Ting.Expression and significance of METTL3 and IREB2 in non-small cell lung cancer tissues[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2026,35(03):240-244.
吴锦伟,承婷.METTL3、IREB2在非小细胞肺癌组织中的表达及意义[J].局解手术学杂志,2026,35(03):240-244. DOI: 10.11659/jjssx.06E025123.
WU Jin-wei,CHENG Ting.Expression and significance of METTL3 and IREB2 in non-small cell lung cancer tissues[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2026,35(03):240-244. DOI: 10.11659/jjssx.06E025123.
目的
2
探讨甲基转移酶样蛋白3(METTL3)、铁反应元件结合蛋白2(IREB2)在非小细胞肺癌(NSCLC)组织中的表达及其临床意义。
方法
2
本研究为回顾性队列研究,纳入2021年1月至2023年3月无锡市第二人民医院收治的102例NSCLC患者为研究对象,另选取100例肺部良性病变患者作为正常对照。RT-PCR法检测正常肺组织、癌组织及癌旁组织中METTL3、IREB2的表达水平。收集所
有患者临床资料,分析METTL3、IREB2与NSCLC患者临床病理特征的关系;依据随访情况,将NSCLC患者分为生存组和死亡组,单因素分析及多因素
Cox
回归分析影响NSCLC患者预后的因素;绘制受试者工作特征(
ROC
)曲线,评估METTL3、IREB2对NSCLC患者预后的预测价值。
结果
2
NSCLC患者癌组织中METTL3的表达水平高于癌旁组织,而IREB2的表达水平低于癌旁组织,差异均具有统计学意义(
P
<
0.001)。与TNM分期Ⅰ~Ⅱ期和无淋巴结转移患者相比,Ⅲ~Ⅳ期和淋巴结转移患者的癌组织中METTL3表达水平显著升高,IREB2表达显著降低,差异均具有统计学意义(
P
<
0.05)。多因素
Cox
回归分析结果显示,TNM分期Ⅲ~Ⅳ期、淋巴结转移、METTL3高表达及IREB2低表达均是影响NSCLC患者预后的独立危险因素(
P
<
0.05)。
ROC
曲线分析结果显示,NSCLC患者癌组织中METTL3、IREB2联合预测预后的曲线下面积(
AUC
)为0.865,敏感度89.30%,特异度78.36%,均高于二者单独预测。
结论
2
NSCLC患者癌组织中METTL3高表达、IREB2低表达与临床病理特征密切相关,是导致患者不良预后的独立危险因素,且二者联合对NSCLC患者不良预后具有较高的预测价值。
Objective
2
To investigate the expression and clinical significance of methyltransferase-like protein 3 (METTL3) and iron responsive element binding protein 2 (IREB2) in non-small cell lung cancer (NSCLC) tissues.
Methods
2
This retrospective cohort study enrolled 102 NSCLC patients admitted to Wuxi Second People's Hospital from January 2021 to March 2023, and 100 patients with benign lung lesions served as the normal control. The expression levels of METTL3 and IREB2 in normal lung tissues, tumor tissues, and paracancerous tissues were detected by RT-PCR. The clinical data of all patients were collected, and the relationships of METTL3 and IREB2 expression with the clinicopathological features of NSCLC patients were analyzed. Based on the follow-up status, NSCLC patients were divided into the survival group and the death group. Univariate analysis and multivariate
Cox
regression analysis were conducted to analyze the factors affecting the prognosis of NSCLC patients.
Receiver operating characteristic
(
ROC
) curve was plotted to evaluate the predictive value of METTL3 and IREB2 for the progno
sis in NSCLC patients.
Results
2
The expression level of METTL3 in tumor tissues of NSCLC patients was higher than that in paracancerous tissues, while the expression level of IREB2 was lower than that in paracancerous tissues, with statistically significant differences (
P
<
0.001). Compared with patients at TNM stages Ⅰto Ⅱ or those without lymph node metastasis, the expression level of METTL3 was significantly increased and IREB2 was significantly decreased in cancer tissues of patients at stages Ⅲto Ⅳ or those with lymph node metastasis, with statistically significant differences (
P
<
0.05). Multivariate
Cox
regression analysis results indicated that TNM stages Ⅲ to Ⅳ, lymph node metastasis, high METTL3 expression, and low IREB2 expression were all the independent risk factors for the poor prognosis in NSCLC patients (
P
<
0.05).
ROC
curve analysis showed that the combined use of METTL3 and IREB2 expression in cancer tissues predicted the prognosis of NSCLC patients with an area under the curve of 0.865, a sensitivity of 89.30%, and a specificity of 78.36%, all of which were higher than those of either marker alone.
Conclusion
2
The high expression of METTL3 and low expression of IREB2 in tumor tissues of NSCLC patients are closely associated with clinicopathological features, and serve as independent risk factors for poor prognosis of patients.Furthermore, the combination of these two markers demonstrates high predictive value for poor prognosis in NSCLC patients.
Bray F , Laversanne M , Sung H , et al . Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2024 , 74 ( 3 ): 229 - 263 . doi: 10.3322/caac.21834 http://dx.doi.org/10.3322/caac.21834 .
郑健豪 , 柯希贤 , 宋永祥 . m6A甲基化修饰和非编码RNA在非小细胞肺癌中串扰的研究进展 [J]. 遵义医科大学学报 , 2024 , 47 ( 11 ): 1122 - 1133 . doi: 10.14169/j.cnki.zunyixuebao.2024.0149 http://dx.doi.org/10.14169/j.cnki.zunyixuebao.2024.0149 .
Wang T , Kong S , Tao M , et al . The potential role of RNA N6-methyladenosine in cancer progression [J]. Mol Cancer , 2020 , 19 ( 1 ): 88 . doi: 10.1186/s12943-020-01204-7 http://dx.doi.org/10.1186/s12943-020-01204-7 .
陈珊珊 , 李高峰 . METTL3 m6A修饰调控与肿瘤发病机制的研究进展 [J]. 四川医学 , 2024 , 45 ( 6 ): 665 - 669 . doi: 10.16252/j.cnki.issn.1004-0501-2024.06.018 http://dx.doi.org/10.16252/j.cnki.issn.1004-0501-2024.06.018 .
唐欣 . 姜黄素对肺癌细胞铁死亡的影响及机制研究 [D]. 天津 : 天津医科大学 , 2021 . doi: 10.27366/d.cnki.gtyku.2021.001399 http://dx.doi.org/10.27366/d.cnki.gtyku.2021.001399 .
谭国耀 , 蔡珮蘅 , 曹霖 , 等 . 隐丹参酮对肺癌细胞铁死亡相关基因表达的影响 [J]. 中国药理学通报 , 2019 , 35 ( 12 ): 1654 - 1659 . doi: 10.3969/j.issn.1001-1978.2019.12.007 http://dx.doi.org/10.3969/j.issn.1001-1978.2019.12.007 .
李名杨 , 陶爽 , 李国辉 . m6A调控细胞自噬和铁死亡途径影响肿瘤细胞生长 [J]. 中国生物化学与分子生物学报 , 2024 , 40 ( 9 ): 1222 - 1229 . doi: 10.13865/j.cnki.cjbmb.2024.07.1117 http://dx.doi.org/10.13865/j.cnki.cjbmb.2024.07.1117 .
中华医学会 , 中华医学会肿瘤分会 , 中华医学会杂志社 . 中华医学会肺癌临床诊疗指南(2018版) [J]. 中华肿瘤杂志 , 2018 , 40 ( 12 ): 935 - 964 . doi: 10.3760/cma.j.issn.0253-3766.2018.12.012 http://dx.doi.org/10.3760/cma.j.issn.0253-3766.2018.12.012 .
周彩存 , 王洁 , 步宏 , 等 . 中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2019年版) [J]. 中国肺癌杂志 , 2020 , 23 ( 2 ): 65 - 76 . doi: 10.3779/j.issn.1009-3419.2020.02.01 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.02.01 .
Jin Q , Qu H , Quan C . New insights into the regulation of METTL3 and its role in tumors [J]. Cell Commun Signal , 2023 , 21 ( 1 ): 334 . doi: 10.1186/s12964-023-01360-5 http://dx.doi.org/10.1186/s12964-023-01360-5 .
Liu F , Chen Y , Chen B , et al . MiR-935 promotes clear cell renal cell carcinoma migration and invasion by targeting IREB2 [J]. Cancer Manag Res , 2019 , 11 : 10891 - 10900 . doi: 10.2147/CMAR.S232380 http://dx.doi.org/10.2147/CMAR.S232380 .
Shao L , Zhu L , Su R , et al . Baicalin enhances the chemotherapy sensitivity of oxaliplatin-resistant gastric cancer cells by activating p53-mediated ferroptosis [J]. Sci Rep , 2024 , 14 ( 1 ): 10745 . doi: 10.1038/s41598-024-60920-y http://dx.doi.org/10.1038/s41598-024-60920-y .
Du Y , Hou G , Zhang H , et al . SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function [J]. Nucleic Acids Res , 2018 , 46 ( 10 ): 5195 - 5208 . doi: 10.1093/nar/gky156 http://dx.doi.org/10.1093/nar/gky156 .
Liu S , Zhuo L , Wang J , et al . METTL3 plays multiple functions in biological processes [J]. Am J Cancer Res , 2020 , 10 ( 6 ): 1631 - 1646 .
Xu Y , Lv D , Yan C , et al . METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m6A modification [J]. Cancer Cell Int , 2022 , 22 ( 1 ): 11 . doi: 10.1186/s12935-021-02433-6 http://dx.doi.org/10.1186/s12935-021-02433-6 .
金丹 , 邵爽 , 李睿 , 等 . METTL3促进非小细胞肺癌细胞增殖、迁移和EMT [J]. 安徽医科大学学报 , 2025 , 60 ( 5 ): 928 - 937 . doi: 10.19405/j.cnki.issn1000-1492.2025.05.021 http://dx.doi.org/10.19405/j.cnki.issn1000-1492.2025.05.021 .
伍义文 , 曹健斌 , 黄维佳 , 等 . m6A甲基转移酶METTL3介导miR-127调控非小细胞肺癌细胞系自噬的机制研究 [J]. 现代检验医学杂志 , 2022 , 37 ( 2 ): 12 - 16 . doi: 10.3969/j.issn.1671-7414. 2022.02.003 http://dx.doi.org/10.3969/j.issn.1671-7414.2022.02.003 .
Ziółkowska-Suchanek I , Mosor M , Gabryel P , et al . Susceptibility loci in lung cancer and COPD:association of IREB2 and FAM13A with pulmonary diseases [J]. Sci Rep , 2015 , 5 : 13502 . doi: 10.1038/srep13502 http://dx.doi.org/10.1038/srep13502 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621